TLX · Telix Pharmaceuticals Ltd · Debt
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Borrowings | 2026-06-30 | USD 516,385,000 | 6-K filed 2026-08-20 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Current bonds issued, including current portion of noncurrent bonds | 2026-06-30 | USD 10,818,000 | 6-K filed 2026-08-20 |
| Current secured bank loans received, including current portion of noncurrent secured bank loans | 2026-06-30 | USD 690,000 | 6-K filed 2026-08-20 |
| Lease liabilities | 2026-06-30 | USD 63,476,000 | 6-K filed 2026-08-20 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent bonds issued | 2026-06-30 | USD 496,237,000 | 6-K filed 2026-08-20 |
| Noncurrent secured bank loans received | 2026-06-30 | USD 8,716,000 | 6-K filed 2026-08-20 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.